Arizona Algae and Nooter/Eriksen Announce Partnership in Development and Commercialization of Extracted and Refined Algae Products

St. Louis, MO and Holbrook, AZ, July 11, 2022 — Arizona Algae Products, LLC, a leading algae producer and innovative biotechnology company and Nooter/Eriksen, Inc., a global leader in sustainable energy, today announced that the companies have entered into a strategic partnership for the development and commercialization of extracted and refined algae products, with an initial focus on algal EPA omega-3 oils. The partnership leverages the companies’ complementary skill sets in advancing the methods and production capabilities for a variety of algae products.Continue reading

First in Human Subjects Enrolled in Aqualung Therapeutics Phase 1A Study Evaluating Safety, Tolerability and Pharmacokinetics of ALT-100

TUCSON, AZ / ACCESSWIRE / July 5, 2022 / Aqualung Therapeutics, an early stage immunotherapeutics biotech company developing an anti-inflammatory therapeutic platform for serious unchecked inflammatory disorders, announced today that their first two patients have been enrolled in the phase 1A healthy human volunteer Study. The data from this study will be used to understand and validate dosing and safety of the humanized monoclonal antibody therapeutic ALT-100 for future clinical trials that address diseases driven by unchecked inflammation.Continue reading

Substantial ROI Expected From Center for Advanced Molecular and Immunological Therapies

Economic estimates show a new University of Arizona Health Sciences center will positively impact job growth and enhance incomes and tax revenues.

The Center for Advanced Molecular and Immunological Therapies will provide staff, facilities, support and services to advance precision medicine while anchoring a biosciences innovation hub on the Phoenix Bioscience Core.

Continue reading

Publication Highlights Potential Clinical Applications of the HTG Transcriptome Panel in Bladder Cancer

TUCSON, Ariz., June 29, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product’s commercial release.Continue reading

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations

Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022.  

New data from pooled analysis shows DecisionDx®-Melanoma can identify patients at a high risk of melanoma recurrence within a patient population deemed low risk (T1, ≤1mm) by traditional staging systems

  • Survey of 400 dermatologic clinicians demonstrates how DecisionDx®-SCC results can lead to risk-aligned treatment plan changes for patients with high-risk squamous cell carcinoma
  • Castle’s laboratory workflow for MyPath® Melanoma and DecisionDx® DiffDx®-Melanoma increased the reporting of clinically actionable results to over 99% in a performance cohort of 350 archival biopsy samples

Continue reading

Gene Variation May Be Early Indicator for Gastric Cancer

A new study identified a gene variation that could inform clinicians which patients are more susceptible to developing stomach cancer. Researchers at the University of Arizona Health Sciences are hoping to catch stomach cancer before it develops in at-risk patients. In a paper published in Gastroenterology, researchers identified a genetic variation that could help identify when patients with Helicobacter pylori are more likely to develop stomach cancer.Continue reading